Mga Batayang Estadistika
| LEI | 549300YTKV8DMSMG6K81 |
| CIK | 784199 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Artivion, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV |
|
| August 8, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Addr |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 7, 2025 |
Artivion Reports Second Quarter 2025 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2025 Financial Results Second Quarter Highlights: •Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 millio |
|
| May 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock ATLANTA, GA – (May 2 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive |
|
| May 19, 2025 |
EX-1.01 2 formsd-ex101.htm EX-1.01 Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2024 to December 31, 2024 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) is prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for th |
|
| May 16, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 16, 2025 |
AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 Exhibit 10.1 AMENDED AND RESTATED ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 GENERAL 1.1 Purpose. The Amended and Restated Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) has been established by Artivion, Inc. (the “Company”)1 to (i) attract, retain, and reward persons eligible to participate in the Plan; (ii) motivate Participants (as defined in Section 1.2 below |
|
| May 14, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock ATLANTA, GA – (May 14, 2025) – Arti |
|
| May 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI |
|
| May 5, 2025 |
Artivion Reports First Quarter 2025 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2025 Financial Results First Quarter Highlights: •Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in |
|
| May 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ⬜ Check the appropriate box: ⬜Preliminary Proxy Statement ⬜Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definiti |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| February 28, 2025 |
Exhibit 10.20(d) AMENDMENT NO. 4 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 4 is dated July 22, 2024 (the “Amendment”), and is between Artivion, Inc. (formerly CryoLife, Inc.) located at Lotzernacker 23, 72379 Hechingen, Germany (“Distributor”) and Endospan, Ltd., located at Maskit St. 4 Herzlia Business Park, Herzlia, Israel 46733 (the “Company”). Each of Company and Distributor are s |
|
| February 28, 2025 |
Artivion, Inc. Insider Trading Policy Exhibit 19.1 INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN SECURITIES As adopted on August 6, 2024 EXECUTIVE SUMMARY Insider Trading – (a)It is a violation of U.S. law for directors, officers, employees, and other individuals who possess material nonpublic information about Artivion, Inc. (together with its subsidiaries, the “Company"), or material nonpublic informa |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E |
|
| February 28, 2025 |
Subsidiaries of Artivion, Inc. Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Chile SpA Chile Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion France S.A.S. France Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion India Private Limited India Artivion Italy s.r.l. Italy Artivion LATAM Holdings Spain, SLU Spain Ar |
|
| February 28, 2025 |
Description of Artivion, Inc.’s Securities under Section 12 of the Exchange Act. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Artivion, Inc., a Delaware corporation (the "Company"), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): Common Stock. Description of Common Stock The following descri |
|
| February 24, 2025 |
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Highlights: •Achieved revenue of $97.3 million in the fourth quarter of 2024 versus |
|
| February 24, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 9, 2024 |
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis ATLANTA, GA – (December 9, 2024) – Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular sur |
|
| November 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Artivion, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under t |
|
| November 8, 2024 |
AORT / Artivion, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Artivion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 7, 2024 |
Artivion Reports Third Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2024 Financial Results Third Quarter Highlights: •Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 28, 2024 |
1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 August 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Charlotte Young and Amanda Ravitz Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 1, 2024 File No. 001-13165 Ladies and Gentlemen: We are submitting this letter in respon |
|
| August 9, 2024 |
Exhibit 10.1 FIRST AMENDMENT This FIRST AMENDMENT, dated as of June 13, 2024 (this “Amendment Agreement”), to the CREDIT AND GUARANTY AGREEMENT, dated as of January 18, 2024 (the “Credit Agreement”), among ARTIVION, INC., a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party thereto from time to time, the LENDERS party thereto and ARES CAPITAL CORPORATION, as Administrative Age |
|
| August 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV |
|
| August 9, 2024 |
Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY Amended and Restated Loan Agreement This Amended and Restated Loan Agreement (the “Agreement”) is made and entered into as of the 1st day of July, 2024 (the “Effective Date”), by and between Artivion, Inc., a Delaware corporati |
|
| August 8, 2024 |
Artivion Reports Second Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2024 Financial Results Second Quarter Highlights: •Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 1, 2024 |
FOR IMMEDIATE RELEASE Contacts: Artivion, Inc. Lance A. Berry Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Laine Morgan Phone: 332-895-3222 [email protected] Artivion Amends Agreements with Endospan Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purcha |
|
| May 30, 2024 |
Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2023 to December 31, 2023 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive |
|
| May 17, 2024 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARTIVION, INC. (A DELAWARE CORPORATION) (Effective May 15, 2024) ARTICLE I OFFICES Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the “Board”) may from time to time determine or the business of the corporation may requ |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 16, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARTIVION, INC. (Originally incorporated January 1, 2022 under the name CryoLife, Inc.) Artivion, Inc., a corporation organized and existing under the laws of the State of Delaware, DOES HEREBY CERTIFY AS FOLLOWS: 1.The name of the corporation is “Artivion, Inc.” The original certificate of incorporation was filed with the Secretary o |
|
| May 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI |
|
| May 6, 2024 |
Artivion Reports First Quarter 2024 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2024 Financial Results First Quarter Highlights: •Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| March 21, 2024 |
PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION DATED March 21, 2024 In accordance with Rule 14a-6(d) under Regulation 14A, please be advised that Artivion, Inc. |
|
| March 11, 2024 |
AORT / Artivion, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d763985dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artivion, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 228903100 (CUSIP Number) February 28, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| March 11, 2024 |
EX-99.1 2 d763985dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 11, 2024 |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Artivion, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo |
|
| March 1, 2024 |
Exhibit 4.2 ARTIVION, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 3 Section 1.4. Rules of Construction 3 ARTICLE II. THE SECURITIES Section 2.1. Issuable in Series 4 Section 2.2. Establishment of Term |
|
| February 23, 2024 |
Exhibit 10.21(c) CERTAIN INFORMATION HAS BEEN OMITTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 3 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 3 is dated 1st October 2023 (the “Amendment”), and is between JOTEC GmbH, a wholly-owned subsidiar |
|
| February 23, 2024 |
Exhibit 10.23 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY CONFIDENTIAL December 4, 2023 Mr. D. Ashley Lee [REDACTED] [REDACTED] Re: Retirement Eligibility Dear Ashley: It is with great pleasure that I inform you that the Compensation Committee (the “Committee”) of the Board of Direct |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E |
|
| February 23, 2024 |
Exhibit 10.26 ARTIVION, INC. CHANGE OF CONTROL SEVERANCE AGREEMENT This Change of Control Severance Agreement (this “Agreement”) dated as of the 4th day of December, 2023 is made and entered into by and between Artivion, Inc., a Delaware corporation (“Artivion” or the “Company”) and Lance A. Berry (the “Executive”). RECITALS 1. It is expected that the Company from time to time will consider the po |
|
| February 23, 2024 |
Artivion, Inc., Updated Clawback Policy, as amended August 2023. Exhibit 97.1 ARTIVION, INC. UPDATED CLAWBACK POLICY As Amended August 2023 In the event Artivion, Inc. (the “Company”) issues a material accounting restatement of its financial statements, or issues a restatement that corrects errors that are not material to previously issued financial statements, but that would result in a material misstatement if corrected or left uncorrected in a current financ |
|
| February 23, 2024 |
Exhibit 10.3(h) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the “Notice of Grant” |
|
| February 23, 2024 |
Subsidiaries of Artivion, Inc. Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Chile SpA Chile Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion LATAM Holdings Spain, SLU Spain Artivion Malaysia, Sdn. Bhd. Malaysia Artivion New Zealand New Zealand Artivion Polska Sp. z.o.o. |
|
| February 23, 2024 |
Exhibit 10.24 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of this 1st day of January 2024 (“Effective Date”) by and between Artivion, Inc., on its own behalf and on behalf of its affiliates (collectively, |
|
| February 23, 2024 |
Exhibit 10.3(j) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the “Notice of Grant” |
|
| February 23, 2024 |
Exhibit 10.27 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY December 6, 2023 Ms. Amy D. Horton [REDACTED] [REDACTED] Re: Performance and Retention Bonus Dear Amy: It is with great pleasure that I inform you that the Board of Directors of Artivion, Inc. (the “Company”) has approved, upo |
|
| February 23, 2024 |
Exhibit 10.3(f) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term |
|
| February 23, 2024 |
Exhibit 10.3(g) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term |
|
| February 23, 2024 |
Summary of 2023 Compensation Arrangements with Non-Employee Directors. Exhibit 10.6 SUMMARY OF 2023 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2023) The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2023. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director. |
|
| February 23, 2024 |
Offer Letter, dated December 4, 2023, by and between Artivion, Inc. and Lance A. Berry. Exhibit 10.25 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY November 10, 2023 Via email: [REDACTED] Mr. Lance Berry [REDACTED] [REDACTED] Dear Lance: It is with great pleasure that I am writing this letter to outline our offer to you to join Artivion, Inc. (“Artivion” or the “Company”) |
|
| February 23, 2024 |
Exhibit 10.3(i) Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the “Notice of Grant”) and the Term |
|
| February 15, 2024 |
Artivion Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston / Laine Morgan Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2023 Financial Results Fourth Quarter and Recent Business Highlights: •Achieved revenue of $93.7 million in the fourth qu |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2024 |
EX-99.B 3 d748547dex99b.htm EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited incorporated by reference to 13G filings made by Macquarie Group Limited on June 7, 2023. Page 13 of 13 |
|
| February 14, 2024 |
EX-99.A 2 d748547dex99a.htm EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this [7th] day of FEBRUARY, 2024 by and between Delaware Funds by Macquarie,® Optimum Fund Trust and Macquarie ETF Trust listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectiv |
|
| February 14, 2024 |
AORT / Artivion, Inc. / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d748547dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 13, 2024 |
AORT / Artivion, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0340-artivioninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Artivion Inc Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p |
|
| February 8, 2024 |
AORT / Artivion, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ARTIVION, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 18, 2024 |
Exhibit 10.1 EXECUTION VERSION $350,000,000 CREDIT AND GUARANTY AGREEMENT dated as of January 18, 2024 by and among ARTIVION, INC., as Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER FROM TIME TO TIME PARTY HERETO, as Guarantor Subsidiaries, The Lenders From Time to Time Party Hereto, and ARES CAPITAL CORPORATION, as Administrative Agent and Collateral Agent ARES CAPITAL MANAGEMENT LLC, as Sole Lea |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 18, 2024 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 6, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President, Phone: 332-895-3222 Finance [email protected] Phone: 770-419-3355 Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer Reaffirms Financial Guidance Provided |
|
| November 3, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 |
|
| November 3, 2023 |
Exhibit 10.3(e) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FIFTH AMENDMENT TO LEASE AGREEMENT This FIFTH AMENDMENT TO LEASE AGREEMENT (FIFTH AMENDMENT) is made and entered into on this 11th day of September 2023 by an |
|
| November 3, 2023 |
Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , between ARTIVION, INC., a Delaware corporation (the “Corporation”), and , a resident of (the “Indemnitee”). W I T N E S S E T H WHEREAS, at the request of the Corporation, Indemnitee is an executive officer and/or a member of the board of directors of the Corporation (the “Boar |
|
| November 3, 2023 |
Exhibit 10.3(d) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FOURTH AMENDMENT TO LEASE AGREEMENT This FOURTH AMENDMENT TO LEASE AGREEMENT (FOURTH AMENDMENT) is made between 1300 E. ANDERSON LANE, LTD., (LANDLORD), and C |
|
| November 2, 2023 |
Artivion Reports Third Quarter 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2023 Financial Results Third Quarter and Recent Business Highlights: •Achieved revenue of $87.9 million in the third quarter of 2023 versus |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 18, 2023 |
1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 1655 Roberts Boulevard, N.W. Kennesaw, Georgia 30144 August 18, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford and Amanda Ravitz Re: Artivion, Inc. Definitive Proxy Statement on Schedule 14A Filed April 3, 2023 File No. 001-13165 Ladies and Gentlemen: We are submitting this letter in respon |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 8, 2023 |
to the Registrant’s Current Report on Form 8-K filed Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARTIVION, INC. (A DELAWARE CORPORATION) (Effective September 1, 2023) ARTICLE I OFFICES Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the “Board”) may from time to time determine or the business of the corporation may |
|
| August 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 3, 2023 |
Artivion Reports Second Quarter 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2023 Financial Results Second Quarter and Recent Business Highlights: •Achieved revenue of $89.3 million in the second quarter of 2023 ver |
|
| June 9, 2023 |
S-8 1 forms-82023.htm S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Ken |
|
| June 9, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ARTIVION, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0 |
|
| May 30, 2023 |
Exhibit 1.01 Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2022 to December 31, 2022 Background This Conflict Minerals Report (the “Report”) of Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executive |
|
| May 19, 2023 |
ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 Exhibit 10.1 ARTIVION, INC. 2020 EQUITY AND CASH INCENTIVE PLAN SECTION 1 GENERAL 1.1 Purpose. The Artivion, Inc. 2020 Equity and Cash Incentive Plan (the “Plan”) has been established by Artivion, Inc. (the “Company”)1 to (i) attract, retain, and reward persons eligible to participate in the Plan; (ii) motivate Participants (as defined in Section 1.2 below), by means of appropriate incentives, to |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTI |
|
| May 4, 2023 |
Artivion Reports First Quarter 2023 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports First Quarter 2023 Financial Results First Quarter and Recent Business Highlights: •Achieved revenue of $83.2 million in the first quarter of 2023 versus |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| February 23, 2023 |
Exhibit 10.13(c) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Amendment Form Amendment No. 3 Amendment Submission Date: November 18, 2022 Sponsor: Artivion, Inc. Study Title: PROACT Xa - Prospective Randomized On-X Anti |
|
| February 23, 2023 |
Exhibit 10.14(d) EXECUTION VERSION FOURTH AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AND GUARANTY AGREEMENT is dated as of December 19, 2022 (this “Fourth Amendment”), and entered into by and among Artivion, Inc. (f/k/a CryoLife, Inc.), a Delaware corporation (the “Borrower”), the Guarantor Subsidiaries party hereto, the Lenders party hereto and Deutsche Bank AG New |
|
| February 23, 2023 |
Description of Artivion, Inc.’s Securities under Section 12 of the Exchange Act. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Artivion, Inc., a Delaware corporation (the “Company”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock. Description of Common Stock The following descri |
|
| February 23, 2023 |
Exhibit 10.13(b) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Amendment Form Amendment No. 2 Amendment Submission Date: January 20, 2022 Sponsor: Artivion, Inc. (formerly CryoLife, Inc.) Study Title: PROACT Xa - Prospec |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. (E |
|
| February 23, 2023 |
Exhibit 10.3(a) Name: %%FIRSTNAMEMIDDLENAMELASTNAME%-% Total No. of Units: %%TOTALSHARESGRANTED%-% ARTIVION RESTRICTED STOCK AWARD AGREEMENT ARTIVION, INC. (“Artivion”) is pleased to grant you the restricted stock award described below (“Stock Award”). This grant is made subject to the further terms and conditions set forth in this Agreement and the terms of the Artivion, Inc. 2020 Equity and Cash |
|
| February 23, 2023 |
Summary of 2022 Compensation Arrangements with Non-Employee Directors. Exhibit 10.6 SUMMARY OF 2022 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2022) The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2022. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director. |
|
| February 23, 2023 |
Exhibit 10.21(b) CERTAIN INFORMATION HAS BEEN OMITTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO EXCLUSIVE DISTRIBUTION AGREEMENT This Amendment No. 2 is dated December 30, 2022 (the “Amendment”), and is between JOTEC GmbH, a wholly-owned subsidia |
|
| February 23, 2023 |
Subsidiaries of Artivion, Inc. Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. Subsidiary Jurisdiction Artivion Colombia SAS Colombia Artivion Cyprus Limited Cyprus Artivion EMEA GmbH Germany Artivion Hellas Single Member Ltd. Greece Artivion Hong Kong, Limited Hong Kong Artivion LATAM Holdings Spain, SLU Spain Artivion Malaysia, Sdn. Bhd. Malaysia Artivion New Zealand New Zealand Ascyrus Medical GmbH Germany Ascyrus Medical LLC Fl |
|
| February 16, 2023 |
Artivion Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter and Recent Business Highlights: •Achieved revenue of $79.4 million in the fourth quart |
|
| February 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2023 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 14, 2023 |
AORT / Artivion Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A 1 d444901dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2023 |
EX-99.B 3 d444901dex99b.htm EX-99.B Exhibit B EXHIBIT B Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021. Page 13 of 13 |
|
| February 14, 2023 |
EX-99.A 2 d444901dex99a.htm EX-99.A Exhibit A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). W |
|
| February 9, 2023 |
AORT / Artivion Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0316-artivioninc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Artivion Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule |
|
| February 6, 2023 |
AORT / Artivion Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Artivion, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 228903100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 4, 2022 |
Exhibit 10.3 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August 2022 is made and entered into by and between Artivion, Inc., a Delaware corpor |
|
| November 4, 2022 |
Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of August 2, 2022, between ARTIVION, INC., a Delaware corporation (the “Corporation”), and , a resident of the State of (the “Indemnitee”). W I T N E S S E T H WHEREAS, at the request of the Corporation, Indemnitee is an executive officer and/or a member of the board of directors of |
|
| November 4, 2022 |
Exhibit 10.2 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August, 2022 is made and entered into by and between Artivion, Inc., a Delaware corpo |
|
| November 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 |
|
| November 4, 2022 |
Exhibit 10.4 CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM THE VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION TO PROTECT PERSONAL PRIVACY ARTIVION, INC. Change of Control Severance Agreement This Change of Control Severance Agreement (this “Agreement”) dated as of the 2nd day of August, 2022 is made and entered into by and between Artivion, Inc., a Delaware corpo |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| November 3, 2022 |
Artivion Reports Third Quarter 2022 Financial Results EX-99.1 2 aort-2022x8k93022ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Third Quarter 2022 Financial Results Third Quarter and Recent Business Highlights: •Achieved revenue of $76. |
|
| September 29, 2022 |
Elizabeth Hoff Joins Artivion Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Elizabeth Hoff Joins Artivion Board of Directors ATLANTA, GA ? (September 29, 2022) ? Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 26, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 26, 2022 |
AORT / Artivion Inc / Juniper Investment Company, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Artivion, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 228903100 (CUSIP Number) John A. Bartholdson Juniper Investment Company, LLC 555 Madison Avenue, 24th Floor New York, New York 10022 (212) 339-8500 (Name, Address and Telephone Num |
|
| September 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 23, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 631-807-1986 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, GA - |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIV |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| August 4, 2022 |
Artivion Reports Second Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC D. Ashley Lee Brian Johnston / Lynn Lewis Executive Vice President & Phone: 332-895-3222 Chief Financial Officer [email protected] Phone: 770-419-3355 Artivion Reports Second Quarter 2022 Financial Results Second Quarter and Recent Business Highlights: ?Achieved revenue of $80.3 million in the second quarter 2022 versus |
|
| May 26, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD ? Specialized Disclosure Report ARTIVION, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal |
|
| May 26, 2022 |
Exhibit 1.01 ? Artivion, Inc. Conflict Minerals Report For the reporting period January 1, 2021 to December 31, 2021 ? Background This Conflict Minerals Report (the ?Report?) of Artivion, Inc. (?Artivion,? the ?Company,? ?we,? or ?us?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar |
|
| May 23, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1655 Roberts Boulevard, N.W. Kennesaw, Georgia 3014 |
|
| May 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables ? Form S-8 (Form Type) ? ARTIVION, INC. |
|
| May 20, 2022 |
Exhibit 10.1 ARTIVION, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN ? May 19, 2022 ? 1. Purpose. The Artivion, Inc. Amended and Restated Employee Stock Purchase Plan (the ?Plan?) is intended to encourage employee stock ownership by offering employees of Artivion, Inc. and its subsidiaries Purchase Rights (as such term is defined in Section 2 hereof) to purchase shares of Common Stock. Th |
|
| May 20, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 ARTIVION, INC. (Exact name of registrant as specified in its charter) Delaware 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2022 |
Exhibit 10.4 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the ?Notice of Grant?) and the Terms a |
|
| May 6, 2022 |
Exhibit 10.1 Artivion, Inc. 1655 Roberts Boulevard N.W. Kennesaw, Georgia 30144 Date of Grant: Name: Address: Re:Grant of Non-Qualified Stock Option Dear This letter sets forth the agreement (the ?Agreement?) between you (?Employee?) and Artivion, Inc., a Delaware corporation (the ?Company?), regarding your option to acquire shares of the Company?s Common Stock. 1.Grant of Option. Subject to the t |
|
| May 6, 2022 |
Exhibit 10.2 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN PERFORMANCE SHARE AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. 2020 Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Performance Share Award Agreement, including the Notice of Stock Unit Grant (the ?Notice of Grant?) and the Terms a |
|
| May 6, 2022 |
Exhibit 10.3 Name: Total No. of Units: ARTIVION, INC. EQUITY AND CASH INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Artivion, Inc. Equity and Cash Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Unit Award Agreement, including the Notice of Restricted Stock Unit Grant (the ?Notice of Grant?) a |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 ARTIVION, INC. (Exact |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 5, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fil |
|
| May 5, 2022 |
Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? Artivion D. Ashley Lee Executive Vice President & Chief Financial Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 [email protected] ? Artivion Reports First Quarter 2022 Financial Results ? Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 |
|
| April 4, 2022 |
1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT ARTIVION, INC. | 2022 Proxy Statement ? ? 1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT April 4, 2022 To Our Stockholders: On behalf of the Board of Directors, we invite you to attend the Annual Meeting of Stockholders of Artivion, Inc. on May 18, 2022 at 9:00 a.m., EDT. Due to the continuing health and safety concerns from the COVID-19 pandemic an |
|
| April 4, 2022 |
ANNUAL MEETING OF STOCKHOLDERS OF May 18, 2022 PROXY VOTING INSTRUCTIONS ANNUAL MEETING OF STOCKHOLDERS OF May 18, 2022 PROXY VOTING INSTRUCTIONS INTERNET - Access ?www. |
|
| February 22, 2022 |
Summary of 2021 Compensation Arrangements with Non-Employee Directors. Exhibit 10.6 SUMMARY OF 2021 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2021) ? The following summarizes the compensation and benefits received by the non-employee Directors of Artivion as of December 31, 2021. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director |
|
| February 22, 2022 |
Subsidiaries of Artivion, Inc. Exhibit 21.1 SUBSIDIARIES OF ARTIVION, INC. ? ? Subsidiary Jurisdiction Ascyrus Medical GmbH Germany Ascyrus Medical LLC Florida AuraZyme Pharmaceuticals, Inc. Florida CryoLife Asia Pacific, PTE. Ltd Singapore CryoLife Beijing Medical Device Ltd. China CryoLife Canada, Inc. Canada CryoLife Europa, Ltd. England and Wales CryoLife France, SAS. France CryoLife Germany HoldCo GmbH. Germany CryoLife Ge |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 ARTIVION, INC. ?( |
|
| February 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): February 17, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissi |
|
| February 17, 2022 |
Artivion Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: ? ? Artivion D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 332-895-3222 [email protected] ? ? Artivion Reports Fourth Quarter and Full Year 2021 Financial Results ? Fourth Quarter and Recent Business Highlights: ? Achieved re |
|
| February 14, 2022 |
CRY / Cryolife Inc / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Artivion Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 9, 2022 |
CRY / Cryolife Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: CryoLife Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 20, 2022 |
EX-3.1 2 cry-20220118xex31.htm EX-3.1 Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION CryoLife, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. That the following resolution was duly adopted by unanimous written consen |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): January 18, 2022 ? ARTIVION, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissio |
|
| January 20, 2022 |
Exhibit 3.2 ? BYLAWS OF Artivion, Inc. (A DELAWARE CORPORATION) ? ARTICLE I OFFICES ? Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the ?Board?) may from time to time determine or the business of the corporation may require. The corporation?s principal office |
|
| January 20, 2022 |
Exhibit 99.1 ? ? FOR IMMEDIATE RELEASE Contacts: ? ? 631-807-1986 CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Announces Corporate Rebranding and Changes Name to Artivion ? Artivion to Host Investor & Analyst Day on March |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-A/A ? (Amendment No. 1) ? FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ? CryoLife, Inc. (Exact name of registrant as specified in its charter) ? ? Delaware 59-2417093 (State of incorporation or organization) (I.R.S. Employer Identification No |
|
| January 4, 2022 |
Exhibit 2.1 PLAN OF CONVERSION FOR CONVERTING CRYOLIFE, INC., a Florida corporation TO CRYOLIFE, INC., a Delaware corporation ? This Plan of Conversion (together with all of the exhibits attached hereto, this ?Plan?), effective January 1, 2022, is hereby adopted by CryoLife, Inc., a Florida corporation (the ?Corporation?), in order to set forth the terms, conditions, and procedures governing the c |
|
| January 4, 2022 |
BYLAWS CRYOLIFE, INC. (A DELAWARE CORPORATION) Exhibit 3.3 BYLAWS OF CRYOLIFE, INC. (A DELAWARE CORPORATION) ? ARTICLE I OFFICES ? Section 1. Principal and Business Offices. The corporation may have such principal and other business offices, either within or without the State of Delaware, as the Board of Directors (the ?Board?) may from time to time determine or the business of the corporation may require. The corporation?s principal office is |
|
| January 4, 2022 |
Exhibit 3.2 CERTIFICATE OF INCORPORATION OF CRYOLIFE, INC. ? I, the undersigned, for the purposes of incorporating and organizing a corporation under the General Corporation Law of the State of Delaware (?DGCL?), do execute this certificate of incorporation and do hereby certify as follows: ? ARTICLE I NAME ? The name of the corporation shall be CryoLife, Inc. ? ARTICLE II EXISTENCE OF CORPORATION |
|
| January 4, 2022 |
Articles of Conversion Florida Profit Corporation Non-Florida Business Entity Exhibit 3.4 Articles of Conversion For Florida Profit Corporation Into Non-Florida Business Entity ? These Articles of Conversion are submitted to convert the following Florida Profit Corporation into a Delaware Profit Corporation in accordance with Section 607.11933 of the Florida Business Corporation Act (the ?FBCA?). ? 1. The name of the Florida Profit Corporation converting into the resulting |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): January 1, 2022 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Delaware 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission |
|
| January 4, 2022 |
Exhibit 3.1 STATE OF DELAWARE ? CERTIFICATE OF CONVERSION FROM A NON-DELAWARE CORPORATION TO A DELAWARE CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW ? 1.The jurisdiction where the Non-Delaware Corporation was first incorporated, and immediately prior to filing this Certificate of Conversion, is the State of Florida. ? 2.The date on which the Non-Delaware Corporation |
|
| November 18, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2021 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 5, 2021 |
FORM 10-Q TABLE OF CONTENTS Part I – FINANCIAL INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exa |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 4, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission |
|
| November 4, 2021 |
CryoLife Reports Third Quarter 2021 Financial Results Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports Third Quarter 2021 Financial Results ? Third Quarter and Recent Business Highlights: |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| September 22, 2021 |
EX-99.1 2 cry-20210920xex991.htm EX-99.1 Exhibit 99.1 N E W S R E L E A S E FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer, and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] Anthony Semedo Joins CryoLife Board of Directors ATLANTA, GA – |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): September 20, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commissi |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 ? ? As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| July 30, 2021 |
FORM 10-Q TABLE OF CONTENTS Part I – FINANCIAL INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact na |
|
| July 30, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT THIS THIRD AMENDMENT TO CREDIT AND GUARANTY AGREEMENT is dated as of June 2, 2021 (this ?Third Amendment?), and entered into by and among CryoLife, Inc., a Florida corporation (the ?Borrower?), the Guarantor Subsidiaries party hereto, the Lenders party hereto and Deutsche Bank AG New York Branch, as Administrative Agent. RECITALS: WHERE |
|
| July 29, 2021 |
CryoLife Announces Sale of PerClot to Baxter Exhibit 99.2 FOR IMMEDIATE RELEASE Contacts: ? ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Announces Sale of PerClot to Baxter Atlanta, GA ? (July 29, 2021) ? CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular s |
|
| July 29, 2021 |
CryoLife Reports Second Quarter 2021 Financial Results Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports Second Quarter 2021 Financial Results ? Second Quarter and Recent Business Highlights |
|
| July 29, 2021 |
Exhibit 2.1 Execution Copy ASSET PURCHASE AGREEMENT between CRYOLIFE, INC. and BAXTER HEALTHCARE CORPORATION DATED AS OF JULY 28, 2021 ? TABLE OF CONTENTS Page ? Article I DEFINITIONS AND TERMS 1 ? Section 1.1. Definitions 1 Section 1.2. Other Definitional Provisions 9 ? Article II PURCHASE AND SALE 9 ? Section 2.1. Purchase and Sale of Assets 9 Section 2.2. PMAs 9 Section 2.3. Excluded Assets 10 |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): July 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fi |
|
| June 2, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 2, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fil |
|
| May 28, 2021 |
Exhibit 1.01 CryoLife, Inc. Conflict Minerals Report For the reporting period January 1, 2020 to December 31, 2020 ? Background ? This Conflict Minerals Report (the ?Report?) of CryoLife, Inc. (?CryoLife,? the ?Company,? ?we,? or ?us?) has been prepared pursuant to Rule 13p-1 and Form SD (the ?Rule?) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period Januar |
|
| May 28, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD ? Specialized Disclosure Report CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal execu |
|
| May 25, 2021 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2021 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact n |
|
| April 30, 2021 |
Exhibit 10.15(d) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? THIRD AMENDMENT TO LEASE ? This Third Amendment to Lease ("Third Amendment'') is entered into by and between THE H.N. AND FRANCES C. BERGER FOUNDATION, a D |
|
| April 29, 2021 |
CryoLife Reports First Quarter 2021 Financial Results Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Contacts: Phone: 770-419-3355 / Lynn Lewis ? CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] ? CryoLife Reports First Quarter 2021 Financial Results ? First Quarter and Recent Business Highlights: |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): April 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission F |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 29, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission F |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 23, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission F |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ?Washington, D.C. 20549 ? FORM 8-K CURRENT REPORT ?PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): March 8, 2021 ? CRYOLIFE, INC. (Exact name of registrant as specified in its charter) ? Florida 1-13165 59-2417093 (State or Other Jurisdiction ?of Incorporation) (Commission Fi |
|
| February 23, 2021 |
Exhibit 10.21(a) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? AMENDMENT No. 1 to EXCLUSIVE Distribution Agreement ? This Amendment No. 1 is dated August 31, 2020 (the ?Amendment?), and is between JOTEC GmbH, a wholly- |
|
| February 23, 2021 |
Exhibit 10.19 ? CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Gewerberaummietvertrag 72379 Hechingen, Lotzen?cker 25, zu errichtender Neubau Commercial Lease Agreement 72379 Hechingen, Lotzen?cker 25, new building to be |
|
| February 23, 2021 |
Subsidiaries of CryoLife, Inc. EX-21.1 7 cry-20201231xex211.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF CRYOLIFE, INC. Subsidiary Jurisdiction Ascyrus Medical GmbH Germany Ascyrus Medical LLC Florida AuraZyme Pharmaceuticals, Inc. Florida CryoLife Asia Pacific, PTE. Ltd Singapore CryoLife Beijing Medical Device Ltd. China CryoLife Canada, Inc. Canada CryoLife Europa, Ltd. England and Wales CryoLife France, SAS. France CryoLife |
|
| February 23, 2021 |
Exhibit 10.15(d) CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED THIRD AMENDMENT TO LEASE ? This Third Amendment to Lease ("Third Amendment'') is entered into by and between THE H.N. AND FRANCES C. BERGER FOUNDATION, a Del |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 CRYOLIFE, INC. ?( |
|
| February 23, 2021 |
Exhibit 10.23(a) ? CERTAIN INFORMATION HAS BEEN OMITTED OR REDACTED FROM VERSION OF THIS EXHIBIT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ? ? Amendment Form ? ? Amendment No. 1 ? Amendment Submission Date: November 17, 2020 ? Sponsor: CryoLife, Inc. ? Study Title: Prospective Randomized On-X |
|
| February 23, 2021 |
Summary of 2020 Compensation Arrangements with Non-Employee Directors. Exhibit 10.6 SUMMARY OF 2020 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2020) ? The following summarizes the compensation and benefits received by the non-employee Directors of CryoLife as of December 31, 2020. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CryoLife Inc (Name of Issuer) Common Shares (Title of Class of Securities) 228903100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 11, 2021 |
CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 cry-20210211xex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] CryoLife Reports Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter and Re |
|
| February 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2021 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: CryoLife Inc. Title of Class of Securities: Common Stock CUSIP Number: 228903100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exa |
|
| November 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 4, 2020 |
CryoLife Reports Third Quarter 2020 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Phone: 770-419-3355 / Lynn Lewis CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] CryoLife Reports Third Quarter 2020 Financial Results Third Quarter and Recent Business Highlights: |
|
| September 2, 2020 |
CryoLife Acquires Ascyrus Medical Conference Call and Webcast Today, September 2, 2020 at 5:00 pm ET EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] CryoLife Acquires Ascyrus Medical Conference Call and Webcast Today, September 2, 2020 at 5:00 pm ET Atlanta, GA – (September 2, 2020) |
|
| September 2, 2020 |
EX-2.1 Exhibit 2.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG CRYOLIFE, INC., ASCYRUS MEDICAL LLC, THE SECURITYHOLDERS LISTED IN SCHEDULE 1 AND FORTIS ADVISORS LLC, AS THE SECURITYHOLDER REPRESENTATIVE Dated as of September 2, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.1 Definitions 1 ARTICLE II PURCHASE AND SALE 2 2.1 Sale and Purchase of the Company Securities 2 2.2 Closing 2 2.3 Acqu |
|
| September 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 11, 2020 |
As filed with the Securities and Exchange Commission on August 11, 2020 Registration No. |
|
| July 31, 2020 |
CryoLife Reports Second Quarter 2020 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Phone: 770-419-3355 / Lynn Lewis CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 [email protected] CryoLife Reports Second Quarter 2020 Financial Results Second Quarter and Recent Business Highlights |
|
| July 31, 2020 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CRYOLIFE, INC. Articles of Restatement 1. The name of the corporation is CRYOLIFE, INC. 2. Restated Articles of Incorporation: This Amendment and Restatement of the Articles of Incorporation does contain an amendment to the Articles requiring shareholder approval. The Board of Directors adopted these Amended and Restated Articles of Incorpora |
|
| July 31, 2020 |
EX-99.2 3 cry-20200731xex992.htm EX-99.2 Exhibit 99.2 CryoLife, Inc. Second Quarter 2020 Earnings Conference Call Transcript July 30, 2020 Greetings, and welcome to CryoLife's Second Quarter 2020 Financial Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Lynn Lewis from the Gilmartin Group. Thank you. |
|
| July 31, 2020 |
Exhibit 10.3 EXECUTION VERSION SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT This SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT is dated as of April 29, 2020 (this “Second Amendment”), and entered into by and among CryoLife, Inc., a Florida corporation (the “Borrower”), the Guarantor Subsidiaries party hereto, the Revolving Lenders party hereto and Deutsche Bank AG New York Branch, as |
|
| July 31, 2020 |
Exhibit 10.1 April 24, 2020 [Name and Address] Dear [●]: CryoLife, Inc. (the “Company”) has analyzed the current impact of the coronavirus (“COVID-19”) pandemic on the Company’s operations, including compensation arrangements with employees and directors. The Company has determined that certain further cost-saving measures should be implemented, which will impact your compensation for at lea |
|
| July 31, 2020 |
ADDITIONAL TERMS AND CONDITIONS OF YOUR RESTRICTED STOCK AWARD Exhibit 10.2 Name: Total No. of Units: CRYOLIFE RESTRICTED STOCK AWARD AGREEMENT CRYOLIFE, INC. (“CryoLife”) is pleased to grant you the restricted stock award described below (“Stock Award”) that supplants the cash retainer compensation that has been involuntarily eliminated for period April 1-September 30, 2020, in order to assist the Company’s preservation of liquidity during the COVID-19 |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact na |
|
| June 23, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION $100,000,000 CRYOLIFE, INC. 4.250% CONVERTIBLE SENIOR NOTES DUE 2025 PURCHASE AGREEMENT June 18, 2020 June 18, 2020 Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Ladies and Gentlemen: CryoLife, Inc., a Florida corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC (the “Initial Purchaser” or “you”) $100,000,000 p |
|
| June 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 23, 2020 |
EX-4.1 Exhibit 4.1 Execution Version CRYOLIFE, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 23, 2020 4.250% Convertible Senior Notes due 2025 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amoun |
|
| June 19, 2020 |
CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 347-620-7010 [email protected] CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering ATLANTA, GA – (June 19, 2020) – CryoLife, Inc. (NYSE: CRY) |
|
| June 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 CryoLife, Inc. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 18, 2020 |
CryoLife Announces Offering of Convertible Senior Notes Due 2025 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 347-620-7010 [email protected] CryoLife Announces Offering of Convertible Senior Notes Due 2025 ATLANTA, GA – (June 18, 2020) – CryoLife, Inc. (NYSE: CRY) (“CryoLife” |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144 (Address of principal executi |
|
| May 22, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-13165 CRYOLIFE INC. (Exact n |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 30, 2020 |
CryoLife Reports First Quarter 2020 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Phone: 770-419-3355 / Lynn Lewis CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 347-620-7010 [email protected] CryoLife Reports First Quarter 2020 Financial Results First Quarter and Recent Business Highlights: |
|
| April 1, 2020 |
CryoLife Provides Business Update in Response to COVID-19 Pandemic FOR IMMEDIATE RELEASE Contacts: CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Gilmartin Group LLC Greg Chodaczek / Lynn Lewis Phone: 646-924-1769 [email protected] CryoLife Provides Business Update in Response to COVID-19 Pandemic ATLANTA, GA – (April 1, 2020) – CryoLife, Inc. (NYSE: CRY), a leading cardiac |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2020 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida 1-13165 59-2417093 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| February 19, 2020 |
Subsidiaries of CryoLife, Inc. Exhibit 21.1 SUBSIDIARIES OF CRYOLIFE, INC. Subsidiary Jurisdiction CryoLife Europa, Ltd England and Wales AuraZyme Pharmaceuticals, Inc. Florida CryoLife International, Inc. Florida CryoLife Asia Pacific, PTE. Ltd Singapore CryoLife France, SAS France On-X Life Technologies Holdings, Inc. Delaware On-X Life Technologies, Inc. Delaware Valve Special Purpose Co., LLC Delaware CryoLife Canada, Inc |
|
| February 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13165 CRYOLIFE, INC. ( |
|
| February 19, 2020 |
Summary of 2019 Compensation Arrangements with Non-Employee Directors. Exhibit 10.5 SUMMARY OF 2019 COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS (Effective as of December 31, 2019) The following summarizes the compensation and benefits received by the non-employee Directors of CryoLife as of December 31, 2019. It is intended to be a summary of compensation arrangements, and in no way is intended to provide any additional rights to any non-employee Director. |
|
| February 19, 2020 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Description of Capital Stock CryoLife Inc., a Florida corporation (the “Company”), is authorized to issue up to 75,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company’s common stock, par value $0.01 per share (“common stock”), i |
